Consultations on new scientific evidence
The European Commission may request ECHA to evaluate the new scientific evidence in relation to certain risks of substances in accordance with entries of Annex XVII.
The consultations aim at collecting the newest scientific evidence on certain risks, most updated market trend, best coverage of uses and applications, enforceability and any other aspects of substances listed in Annex XVII or other substances of concern.
The Agency publishes the outcome of such evaluations as draft review reports and invites stakeholders to provide comments and, in particular, relevant new scientific information that was not included in the draft review report
ECHA may launch consultations in other situations when the restriction process or its implementation requires such actions.